Geoff Martha, the executive in charge of integrating Medtronic's $43 billion Covidien acquisition, tells MassDevice.com that the deal will likely mean more strategic investments for the medical device giant.
Medtronic maintains that its $43 billion acquisition of Covidien and move to Ireland wasn't motivated by tax incentives, but the company is poised to save billions while the company's shareholders are left with a hefty tax of their own.
Here's a look at some of the top regulatory stories for medical device companies this week: Seven questions raised by Medtronic's $43B Covidien acquisition; Medtronic, Covidien merger: Good or bad for medtech innovation?; Medtronic, Covidien merger: Mass. Gov. Deval Patrick says he's had no contact with either company; Volcano closes $117M AtheroMed buy; Incubator group buys prostate treatment tech from Endo Health.
Medtronic names Geoff Martha, its senior vice president for strategy & business development, as chief integration officer as it preps to digest the $43 billion Covidien acquisition.
Covidien launches its Pipeline Flex embolization system in European markets after landing CE Mark earlier this year.
Medtech giant Covidien (NYSE:COV) announced this week that it's prepared to launch its Pipeline Flex embolization devices in Europe.
Covidien files another patent infringement lawsuit against Johnson & Johnson's Ethicon Endo-Surgery division over ultrasound shears technology.
Medtech giants Medtronic and Covidien aren't likely to be very acquisitive after finalizing their $43 billion merger, taking 2 very important players out of the game for startup companies, venture capitalists say.